The Lupine arm is finalizing the acquisition of two brands from Sanofi

Drugmaker Lupine said Wednesday that its European unit has completed the acquisition of two brands from Sanofi.

Lupine Atlantis Holdings SA has completed the acquisition of Aarane in Germany and Nalcrom in Canada and the Netherlands along with associated trademark rights from Sanofi, the Mumbai-based drugmaker said in a statement.

The transaction is part of the company’s strategy to increase its global presence in specialized areas, he added.

The acquisition will strengthen Lupin’s respiratory business in Germany, helping to grow the newly established franchise following the launch of Luforbec.

“This acquisition will strengthen our global position in the treatment of patients suffering from a variety of respiratory diseases and conditions, and will also increase our gastrointestinal care assets, which will expand our portfolio of branded products,” said Fabrice Egros, Lupine president of corporate development.

Aarane (sodium cromoglicate/reproterol hydrochloride inhalation under pressure) is a chromone complex indicated for the symptomatic acute treatment of sudden asthma attacks.

Nalcrom (oral sodium cromoglycate) is used to treat food allergies after appropriate testing for sensitivity to specific allergens in combination with restriction of major allergens.

Lupine shares were trading 3.21% higher at Rs 1,613.45 per piece on the BSE.